A Single Peptide That Activates Three Hormone Receptors Reverses Obesity and Diabetes in Rodents

The monomeric peptide triagonist demonstrated supraphysiological potency with equally balanced activity at GLP-1, GIP, and glucagon receptors, without cross-reactivity at other related receptors. It proved superior to the best available dual coagonists and monoagonists at reducing body weight, enhancing glycemic control, and reversing hepatic steatosis in rodent models of obesity. Genetic knockout, pharmacological blockade, and selective chemical knockout experiments confirmed that each receptor's activity contributed to the overall effect: glucagon increased energy expenditure, GLP-1 reduced caloric intake and improved glucose control, and GIP potentiated the incretin effect while buffering against glucagon's diabetogenic potential.

Researchers rationally designed a monomeric peptide with balanced agonist activity at GLP-1, GIP, and glucagon receptors. They characterized receptor potency and selectivity in cell-based assays, then tested efficacy in multiple rodent models of obesity and diabetes. To prove each receptor contributed, they used genetic knockout mice, pharmacological receptor blockade, and selective chemical knockout approaches. Outcomes included body weight, blood glucose, insulin levels, and liver fat content.

This study was foundational for the concept of multi-receptor peptide agonists for metabolic disease — an approach that has since led to drugs like tirzepatide (GLP-1/GIP dual agonist) reaching the market. By demonstrating that triple agonism could outperform any single- or dual-target approach, it established the principle that harmonizing multiple metabolic pathways produces synergistic benefits that no single drug target can match.

This 2015 paper is one of the foundational studies behind the current revolution in peptide-based obesity and diabetes drugs. The principle it demonstrated — that activating multiple complementary metabolic receptors with a single molecule produces superior outcomes — directly influenced the development of tirzepatide and the ongoing race to develop triple agonists for human use. Retatrutide, a GLP-1/GIP/glucagon triple agonist now in clinical trials, builds on this exact concept.

All experiments were conducted in rodent models, and metabolic responses in mice and rats do not always translate to humans. The study did not address long-term safety concerns such as thyroid C-cell effects or pancreatitis risk, which have been relevant for GLP-1-class drugs. Rodent models of obesity may not capture the full complexity of human metabolic disease. No human pharmacokinetic or tolerability data were generated.